1.635
Alector Inc stock is traded at $1.635, with a volume of 364.34K.
It is down -9.67% in the last 24 hours and down -36.38% over the past month.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
See More
Previous Close:
$1.81
Open:
$1.81
24h Volume:
364.34K
Relative Volume:
0.53
Market Cap:
$181.53M
Revenue:
$21.05M
Net Income/Loss:
$-142.93M
P/E Ratio:
-1.1767
EPS:
-1.3895
Net Cash Flow:
$-184.07M
1W Performance:
-24.31%
1M Performance:
-36.38%
6M Performance:
+34.02%
1Y Performance:
+15.96%
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ALEC
Alector Inc
|
1.635 | 200.96M | 21.05M | -142.93M | -184.07M | -1.3895 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-10-26 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-22-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-22-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-22-25 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-28-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
[Form 4] Alector, Inc. Insider Trading Activity - Stock Titan
Alector (ALEC) CEO sells shares to cover RSU tax obligations - Stock Titan
Alector (ALEC) CFO Berkley sells shares to cover RSU tax obligations - Stock Titan
ALEC (NASDAQ: ALEC) Form 144 lists 3,475 restricted common shares - Stock Titan
Alector (NASDAQ: ALEC) Rule 144 notice lists RSU vesting and stock sales - Stock Titan
Alector (NASDAQ: ALEC) files to sell 132,805 RSU shares after vesting - Stock Titan
Alector halts mid-stage trial for Alzheimer’s candidate developed with GSK - MSN
ALEC Q1 2026 Earnings: Narrower Loss Surprises as Pipeline Progress Highlights Biotech ResilienceGuidance vs Actual - newsline.com
ALEC Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative Pipeline - The Legal Advocate
Alector Shares Up, Focus Turns to Pipeline After Setback - Bez Kabli
ALEC Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises, No Revenue YetQuarterly Earnings - thelegaladvocate.com
Alector Inc. (ALEC) Holds Steady at $2.21 as Key Support and Resistance Levels Come into FocusOrder Block - The Legal Advocate
Number of shareholders of Alector, Inc. – DUS:0Z2 - TradingView
Alector Inc. (ALEC) Shows Resilience: Shares Up 4.25% as Biotech Sector Watches Key LevelsCalendar Spread Trade - The Legal Advocate
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus - Yahoo Finance
Alector (ALEC) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.21High Attention Stocks - Newser
Should You Sell Alector (ALEC) After -2.83% Drop? 2026-05-15Beta Neutral Pair - newsline.com
Polaris entities hold 4.85M ALEC shares (ALEC) — Amendment No.7 - Stock Titan
MSN - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alector (ALEC), Spyre Therapeutics (SYRE) and Perspective Therapeutics (CATX) - The Globe and Mail
TradingKey - TradingKey
Alector Establishes $125 Million At-the-Market Offering - The Globe and Mail
Myles Minter Reiterates Hold on Alector as Late-Stage Trial Failures Trigger Pipeline Reset but Next-Gen Brain Carrier Platform Offers Long-Term Optionality - TipRanks
Alector (ALEC) Reports Q1 Revenue Shortfall Amidst Strategic Dev - GuruFocus
Alector, Inc. Announces $125 Million Common Stock Sales Agreement with TD Securities (USA) LLC - Minichart
Alector: Q1 Earnings Snapshot - theheraldreview.com
Alector posts first quarter 2026 financial results amid new business updates - Traders Union
Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Alector (NASDAQ: ALEC) establishes $125M stock ATM facility - Stock Titan
Alector (NASDAQ: ALEC) files $125M ATM offering with TD Cowen - Stock Titan
Alector (NASDAQ: ALEC) narrows Q1 2026 loss as it refocuses pipeline - Stock Titan
Alector Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Alector | 10-Q: Q1 2026 Earnings Report - Moomoo
Alector | 8-K: Alector Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus - Stock Titan
BRIEF-Alector Q1 Basic EPS USD -0.21 - TradingView
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
MSN Money - MSN
Transcript : Alector, Inc.Special Call - marketscreener.com
Alector Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Morgan Stanley Maintains Alector(ALEC.US) With Sell Rating, Raises Target Price to $2 - Moomoo
Five-Way Obesity Drug Shows Effectiveness in Mice; Alector Stops Alzheimer’s Trial - geneonline.com
Franklin Lexington Private Markets Fund's Alector Inc(ALEC) Holding History - GuruFocus
Morgan Stanley raises Alector stock price target on pipeline focus By Investing.com - Investing.com Australia
Morgan Stanley raises Alector stock price target on pipeline focus - Investing.com
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Alector (ALEC) - The Globe and Mail
Failure of GSK-partnered Alzheimer’s drug a fresh setback for Alector - The Pharma Letter
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alector Inc Stock (ALEC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wong-Sarad Grace | Principal Accounting Officer |
Jun 02 '26 |
Sale |
1.97 |
5,709 |
11,271 |
98,936 |
| Wong-Sarad Grace | Principal Accounting Officer |
Jun 03 '26 |
Sale |
1.88 |
3,475 |
6,543 |
95,461 |
| Berkley Neil Lindsay | CFO & Chief Business Officer |
Jun 02 '26 |
Sale |
1.97 |
19,360 |
38,221 |
379,900 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):